Biotechnology - Biotechnology, Diabetes

Filter

Current filters:

BiotechnologyDiabetes

Popular Filters

1 to 25 of 61 results

Boehringer Ingelheim launches diabetes collaboration with Connexios Life Sciences

Boehringer Ingelheim launches diabetes collaboration with Connexios Life Sciences

06-05-2014

German family-owned drug major Boehringer Ingelheim has announced a global research collaboration with…

BiotechnologyBoehringer IngelheimDiabetesGermanyHealth Medical PharmaHealth Medical PharmaIndiaIngelheim am RheinLicensingMajorResearch

Janssen’s Vokanamet approved in EU for adults with type 2 diabetes

28-04-2014

The European Commission has approved US health care giant Johnson & Johnson subsidiary Janssen-Cilag’s…

BiotechnologyDiabetesEuropeJanssen-CilagJohnson & JohnsonRegulationVokanamet

Hyperion Therapeutics to broaden orphan disease pipeline with buy of Israeli firm

24-04-2014

US biotech firm Hyperion Therapeutics has entered into a definitive agreement to acquire Andromeda Biotech,…

Andromeda BiotechBiotechnologyDiabetesDiaPep277Hyperion TherapeuticsMergers & Acquisitions

Islet Sciences to acquire BHV Pharma along with diabetes and NASH products

Islet Sciences to acquire BHV Pharma along with diabetes and NASH products

13-03-2014

US biotech firm Islet Sciences says it has signed a binding letter of intent to acquire Brighthaven Ventures…

BiotechnologyDiabetesIslet SciencesMergers & AcquisitionsNephrology and Hepatologyremogliflozin

Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech

Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech

11-03-2014

Caisson Biotech, a wholly-owned subsidiary of Heparinex and owner of a patented heparosan-based drug…

BiotechnologyCaisson BiotechDiabetesInflammatory diseasesLicensingMetabolicsNovo Nordisk

Israel's Clal Biotech in talks to sell Andromeda unit

28-02-2014

In an announcement to the Stock Exchange, Israeli firm Clal Biotechnology Industries said that, on February…

Andromeda BiotechBiotechnologyClal BiotechnologyDiabetesDiaPep277Mergers & AcquisitionsTeva Pharmaceutical Industries

Celladon signs option agreement with Servier

24-02-2014

USA-based biotech firm Celladon has entered into an option agreement with French independent drugmaker…

BiotechnologyCelladonDiabetesLicensingServier

Positive results for MicroBiome’s NM504 in type 2 diabetes

18-02-2014

Privately-held US biotech company MicroBiome Therapeutics has released positive top-line results from…

BiotechnologyDiabetesMicroBiome TherapeuticsNM504Research

Shire sheds Dermagraft assets for $300 million in milestone payments

Shire sheds Dermagraft assets for $300 million in milestone payments

17-01-2014

Ireland-headquartered drugmaker Shire (LSE: SHP) has agreed to sell its Dermagraft (human fibroblast-derived…

BiotechnologyDermagraftDiabetesLicensingNorthern EuropeShire

DiaVacs' type 1 diabetes drug candidate gains orphan designation from FDA

DiaVacs' type 1 diabetes drug candidate gains orphan designation from FDA

06-01-2014

US clinical-stage biotech firm DiaVacs has granted orphan drug designation for its type 1 diabetes mellitus…

BiotechnologyDiabetesDiaVacsDV-0100North AmericaRegulationUSA

MannKind resubmits NDA for diabetes drug Afrezza after positive study results

MannKind resubmits NDA for diabetes drug Afrezza after positive study results

14-10-2013

MannKind has resubmitted its New Drug Application to the FDA for the marketing and sale of Afrezza Inhalation…

AfrezzaBiotechnologyDiabetesMannKindNorth AmericaRegulation

Evolva to license EV-077 to Serodus

07-10-2013

Switzerland-based Evolva Holding and Norwegian biopharma company Serodus have signed a binding term…

BiotechnologyDiabetesEV-077EvolvaLicensingNephrology and HepatologyPharmaceuticalSerodus

Approved cancer drug potentially could help treat diabetes, Stanford researchers find

16-09-2013

A pair of studies by researchers at the Stanford University School of Medicine has identified a molecular…

afliberceptBayerBiotechnologyDiabetesEyleaOncologyPharmaceuticalRegeneronResearchSanofiZaltrap

Interim results for ChemoCentryx' CCX140 fail to inspire

12-09-2013

US drug developer ChemoCentryx (Nasdaq: CCXI) announced interim data from an ongoing Phase II study in…

BiotechnologyCCX140ChemoCentryxDiabetesNephrology and HepatologyResearch

ThromboGenics gains rights to DME drug

06-09-2013

Belgium-based biopharma firm ThromboGenics (Euronext Brussels: THR:BR) has entered into a collaboration…

Bicycle TherapeuticsBiotechnologyDiabetesLicensingOphthalmicsPharmaceuticalThromboGenics

Sirona Biochem signs LoI with leading Chinese diabetes company

22-08-2013

Canada's Sirona Biotech (TSX VENTURE:SBM) has signed a letter of intent to provide an exclusive license…

Asia-PacificBiotechnologyDiabetesFosun PharmaLicensingPharmaceuticalSGLT2Sirona BiochemWanbang Pharma

Bioran to invest $427 million in building Russia's largest insulin plant

02-08-2013

Russian biotechnology company Bioran plans to invest up to 14 billion roubles ($427 million) in the establishment…

BioranBiotechnologyDiabetesEuropeFinancialProduction

Adocia re-acquires exclusive rights to insulin analog from US drug major

30-07-2013

French biotech firm Adocia (Euronext Paris: ADOC) has agreed with US pharma major Eli Lilly (NYSE: LLY)…

AdociaBiotechnologyDiabetesEli LillyLicensingPharmaceutical

Isis Pharma stock leaps, as investigational drug shown to reduce triglycerides in Ph II study

25-06-2013

US biotech firm Isis Pharmaceuticals (Nasdaq: ISIS) saw its shares leap as much as 22% to $26.89 on Monday,…

BiotechnologyCardio-vascularDiabetesIsis PharmaceuticalsISIS-APOCIIIrxResearch

AstraZeneca unit links with NGM Biopharma on diabetes and obesity research

17-06-2013

Anglo-Swedish drug major AstraZeneca's (LSE: AZN) US biologics R&D subsidiary MedImmune has entered into…

AstraZenecaBiotechnologyDiabetesLicensingMedImmuneMetabolicsNGM BiopharmaceuticalsPharmaceuticalResearch

1 to 25 of 61 results

Back to top